Journal article · 2020 · Open access

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4

María Maneiro, Nafsika Forte, Maria M. Shchepinova, Cyrille S. Kounde, Vijay Chudasama, James R. Baker, Edward W. Tate

ACS Chemical Biology, 15(6), 1306–1312 · Published 27 April 2020 · DOI 10.1021/acschembio.0c00285

Open PDFView at the publisherCite this paper

In brief

“Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4” is a 2020 journal article by María Maneiro and 6 co-authors, published in ACS Chemical Biology. OpenAlex counts 374 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at ACS Chemical Biology.

Citations
374
Most cited in
2026 (84)
Field-weighted impact
10.14
References
46
Authors
7

Abstract

Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery. Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity and do not discriminate between cells of different types. Here, we describe a strategy for selective protein degradation in a specific cell type. We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody–PROTAC internalization, releasing the active PROTAC and inducing catalytic protein degradation. We show that 3 selectively targets bromodomain-containing protein 4 (BRD4) for degradation only in HER2 positive breast cancer cell lines, while sparing HER2 negative cells. Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 positive cells, leading to the release of active PROTAC in quantities sufficient to induce potent BRD4 degradation. These studies demonstrate proof-of-concept for tissue-specific BRD4 degradation, overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020). Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chemical Biology, 15(6), 1306–1312. https://doi.org/10.1021/acschembio.0c00285

MLA 9

Maneiro, María, et al. “Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.” ACS Chemical Biology, vol. 15, no. 6, 2020, pp. 1306–1312. https://doi.org/10.1021/acschembio.0c00285.

Chicago

Maneiro, María, Nafsika Forte, Maria M. Shchepinova, Cyrille S. Kounde, Vijay Chudasama, James R. Baker, and Edward W. Tate. 2020. “Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.” ACS Chemical Biology 15 (6): 1306–1312. https://doi.org/10.1021/acschembio.0c00285.

Harvard

Maneiro, M. et al. (2020) ‘Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4’, ACS Chemical Biology, 15(6), pp. 1306–1312. doi:10.1021/acschembio.0c00285.

IEEE

M. Maneiro et al., “Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4,” ACS Chemical Biology, vol. 15, no. 6, pp. 1306–1312, 2020, doi: 10.1021/acschembio.0c00285.

BibTeX

@article{maneiro2020antibody,
  title     = {{Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4}},
  author    = {Maneiro, María and Forte, Nafsika and Shchepinova, Maria M. and Kounde, Cyrille S. and Chudasama, Vijay and Baker, James R. and Tate, Edward W.},
  journal   = {ACS Chemical Biology},
  year      = {2020},
  volume    = {15},
  number    = {6},
  pages     = {1306--1312},
  doi       = {10.1021/acschembio.0c00285},
  url       = {https://doi.org/10.1021/acschembio.0c00285}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201411
20201010
20213030
20225151
20236767
20246767
20256363
20268484

Its field-weighted citation impact is 10.14: it has been cited 10.14 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • BRD4
  • HER2-positive breast cancer
  • trastuzumab
  • lysosomal trafficking
  • E3 ubiquitin ligase
  • protein internalization

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020). Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chemical Biology, 15(6), 1306–1312. https://doi.org/10.1021/acschembio.0c00285

How many times has this paper been cited?

374 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at ACS Chemical Biology: sign in and open the PDF from this page.

Who wrote this paper?

María Maneiro, Nafsika Forte, Maria M. Shchepinova, Cyrille S. Kounde, Vijay Chudasama, James R. Baker, Edward W. Tate.

What is the DOI of this paper?

10.1021/acschembio.0c00285, permanently at https://doi.org/10.1021/acschembio.0c00285. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.